z-logo
open-access-imgOpen Access
Clinico-histopathological Profile of Primary Paediatric Intra-abdominal Tumours: a Multi-hospital-Based Study
Author(s) -
Nitin Joseph,
Sharada Rai,
Kshitiz Singhal,
Sreejita Saha,
D Chakraborty,
Gauri Badoni,
Thella Revanth,
Flora D. Lobo
Publication year - 2021
Publication title -
indian journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 16
eISSN - 0976-6952
pISSN - 0975-7651
DOI - 10.1007/s13193-021-01365-x
Subject(s) - medicine , surgical oncology , general surgery , primary (astronomy) , radiology , surgery , physics , astronomy
Paediatric cancers are gradually on the rise in India. Its proportion among children aged < 15 years constitutes close to 5% of the total cancer affected population. A high proportion of this constitutes intra-abdominal tumours. This study was done to study the demographic profile, clinical features and management of intra-abdominal tumours among children. Data of all histopathologically confirmed patients aged < 15 years with various primary intra-abdominal tumours diagnosed from 2009 to 2019 were included in this study. The median age of the patients (n = 50) was 3 years (IQR 1.4, 6). The median age at diagnosis of cancer (n = 23) was 2.5 years (IQR 1, 4). Tumours were more common among males (70%). The most common tumour in this study was Wilm's tumour (17 (34%)). Forty-eight (96%) patients had malignant tumours. Fever was present among the majority (27 (54%)) of the patients. The most common anti-cancer drug used for management was Vincristine, used among 23 patients. Remission was more among infants with Wilm's tumour ( P  = 0.0221) and among patients with Hodgkin's lymphoma (HL) ( P  = 0.0444). Default with treatment was more among patients with stage 4 malignancy ( P  = 0.0186). Recovery following treatment was more among patients with germ cell tumour ( P  = 0.0082). Reasons for default with treatment in the late stages of malignancies need to be identified in future research studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here